生物技术公司Bio-Techne（股票代码：TECH）今日盘中股价大幅下跌15.54%，引起了市场的广泛关注。
消息面上，公司公布的第一季度财务业绩未达市场预期。据数据显示，公司第一季度营收为3.114亿美元，低于分析师普遍预期的3.171亿美元；经调整后每股收益为53美分，也略低于预期的54美分。
业绩不及预期的主要原因是美国学术经费的削减，抑制了市场对其药物研发相关产品的需求。公司最大的蛋白质科学部门销售额下降1%，至2.262亿美元；诊断与基因组学部门收入也下降4%，至8560万美元，均未达到市场预期。公司首席执行官金·凯尔德曼表示，尽管生物技术领域资金状况良好，但尚未转化为广泛的产品需求。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.